Cancer immunotherapy .net
Information for doctors 2
cancerimmunotherapy@yahoo.com
Human cancers sensitive to IL-2
      (usually about 50-70% objective responses)

Lung metastases of renal cell carcinoma
Huland et al. (1994) J. Cancer Res. Clin. Oncol. 120:221
Huland et al. (1997) Cancer J. Sci. Am..3 Suppl.1 , S68
Huland & Heinzer (2003) Curr. Op. Urol. 13, 451
Huland et al. (2003) Folia Biol (Praha) 49,183
Huland & Heinzer (2004) Curr. Op. Urol. 14, 239
Huland et al. (2004) Urologe A
online

Recurrent superficial bladder carcinoma
Tubaro et al. (1995) Eur. Urol. 28, 297
Den Otter et al. (1998) J. Urol. 159, 1183
Grasso et al. (2001) J. Immunother. 24, 184


Nasopharyngeal carcinoma stage III-IV

Jacobs et al. (2005) Cancer Immunol. Immunother. 54, 792

Human cancer being studied
     (therapeutic effect is being studied; less than 10 cases are evaluated)

Mesothelioma

Krastev et al. (2001) Cancer Immunol. Immunother. 50, 226

Hepatocellular carcinoma
Krastev et al. (2003) Hepatogastroenterology 50, 1647
Krastev et al. (2005) World J. Gastroenterol. 11, 5525

Colorectal carcinoma

Krastev et al. (2005) World J. Gastroenterol. 11, 5525

Hemangiosarcoma
Krastev et al. (2005) World J. Gastroenterol. 11, 5525
Interleukin-2 (IL-2)
Mechanism of IL-2 therapy of cancer

Cancers sensitve to IL-2
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2

Experts
I want to co-operate (doctors)
Frequently Asked Questions (FAQs)
Information for doctors
Information for patients
I want to support this research or  more information on the EPTI fund supporting this research
Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands